FHLC News and Press, Fidelity MSCI Health Care Index From 05/12/22

With the world facing inflationary and geopolitical hurdles, economic growth is poised to slow. Shares across sectors have been hit hard. Investors in growth stocks must identify companies with the right features to overcome headwinds to earnings. For further details see: ...

Healthcare, Staples, and Utilities continue to outperform as selling intensifies in the growth style. Investor positioning is still light in the space – even after a year of alpha. While absolute valuations have turned somewhat pricey, the defensive supersector shows decent...

AbbVie is a very high-quality company with strong cash flows, exactly the type of company you want to own if we fall into a recession. But it recently posted disappointing results that caused a selloff. Despite near-term pain, the long-term thesis remains strong. For further...

During the last Fed rate raising cycle, it took the Federal Reserve five years to raise the fed funds rate to 2.50%. The Fed kept rates far too low for far too long and now we are dealing with the consequences. Both fiscal and monetary policy have been highly inflationary, and we are ...

IYH gained 12% during 7 weeks from February 22, and then fell by 9% in the next 3 weeks. IYH posted strong price returns over the medium and long term, but generated 1% yield. Biotechnology and Life Sciences Tools & Services companies historically had cyclical price movements,...

LifeStance Health Group aims to solve mental issues for its clients. The company has seen a very tough year following the IPO, as the business is really losing quite a bit of money. Even after a huge pullback seen already, from a very high valuation from the get-go, I am not attra...

Typically, we look at net new highs as a way to confirm moves in the broader market. At the high last Wednesday, over 90% of S&P 500’s new highs came from defensive sectors. In other words, defensives have been a notable pocket of strength recently. For further de...

Wall Street has been on edge lately, with financial markets roiled by a host of factors: yield curve inversion, rising inflation, rate hikes, a possible recession and geopolitical tensions. In this environment, it’s no surprise that exchange traded funds focused on defensive stocks hav...

Stock markets fell in the first quarter as Russia’s invasion of Ukraine destabilized the growth outlook, amplified concerns about rising interest rates and unleashed geopolitical risks. While the conflict has created many uncertainties, we believe the impact of persistent infla...

The XBI biotech index peaked early last year, and it's now back to where it was in April of 2020. The biopharma stocks got powerfully inflated during 2020 by the pandemic. The biotech stocks are going to need some good news to get moving again. For further details see: B...